SG11201602662YA - Inhibitors of kras g12c - Google Patents
Inhibitors of kras g12cInfo
- Publication number
- SG11201602662YA SG11201602662YA SG11201602662YA SG11201602662YA SG11201602662YA SG 11201602662Y A SG11201602662Y A SG 11201602662YA SG 11201602662Y A SG11201602662Y A SG 11201602662YA SG 11201602662Y A SG11201602662Y A SG 11201602662YA SG 11201602662Y A SG11201602662Y A SG 11201602662YA
- Authority
- SG
- Singapore
- Prior art keywords
- kras
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361889460P | 2013-10-10 | 2013-10-10 | |
US201462034619P | 2014-08-07 | 2014-08-07 | |
US201462052366P | 2014-09-18 | 2014-09-18 | |
TW103135318A TWI659021B (en) | 2013-10-10 | 2014-10-09 | Inhibitors of kras g12c |
JOP/2014/0289A JO3805B1 (en) | 2013-10-10 | 2014-10-09 | Inhibitors of kras g12c |
PCT/US2014/060036 WO2015054572A1 (en) | 2013-10-10 | 2014-10-10 | Inhibitors of kras g12c |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201602662YA true SG11201602662YA (en) | 2016-05-30 |
Family
ID=61800013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602662YA SG11201602662YA (en) | 2013-10-10 | 2014-10-10 | Inhibitors of kras g12c |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP3055290B1 (en) |
JP (1) | JP6559123B2 (en) |
KR (1) | KR20160076519A (en) |
CN (1) | CN106488910B (en) |
AU (1) | AU2014331794C1 (en) |
BR (1) | BR112016008016B8 (en) |
CA (1) | CA2926328C (en) |
EA (1) | EA033689B9 (en) |
IL (1) | IL244699B (en) |
MX (1) | MX2016004360A (en) |
NI (1) | NI201600049A (en) |
NO (1) | NO20160646A1 (en) |
PH (1) | PH12016500538A1 (en) |
SG (1) | SG11201602662YA (en) |
UA (1) | UA119971C2 (en) |
WO (1) | WO2015054572A1 (en) |
ZA (1) | ZA201602245B (en) |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
CN108997225A (en) | 2013-03-14 | 2018-12-14 | 特雷罗药物股份有限公司 | JAK2 and ALK2 inhibitor and its application method |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
WO2016049524A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
CN105712998B (en) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | Azaindole derivatives, preparation method and medical application thereof |
BR112017021869A2 (en) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | substituted quinazoline compounds and methods of use thereof |
MX2017013275A (en) * | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof. |
CN108026046B (en) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins |
JP6869947B2 (en) * | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | Use of substituted quinazoline compound and its G12C mutant KRAS, HRAS and / or NRAS protein as an inhibitor |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
CN107849052B (en) * | 2015-07-31 | 2020-05-12 | 大鹏药品工业株式会社 | Pyrrolo [2, 3-d ] pyrimidine compounds or salts thereof |
WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10689356B2 (en) * | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
CN108473472B (en) * | 2015-10-02 | 2021-02-12 | 圣提内尔肿瘤学有限公司 | 2-aminoquinazoline derivatives as P70S6kinase inhibitors |
JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
KR20180081596A (en) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
MX2018013983A (en) * | 2016-05-18 | 2019-08-16 | Mirati Therapeutics Inc | Kras g12c inhibitors. |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
WO2018112420A1 (en) | 2016-12-15 | 2018-06-21 | The Regents Of The University Of California | Compositions and methods for treating cancer |
DK3558955T3 (en) | 2016-12-22 | 2021-10-25 | Amgen Inc | BENZISOTHIAZOLE, ISOTHIAZOLO [3,4-B] PYRIDINE-, QUINAZOLINE-, PHTHALAZINE-, PYRIDO [2,3-D] PYRIDAZINE- AND PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES LIKE KRAS-GANDERHINH -, PANCREAS OR COLOR RECTAL CANCER |
WO2018140514A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
EP3573954A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
JP2020505395A (en) * | 2017-01-26 | 2020-02-20 | アラクセス ファーマ エルエルシー | Fused N-heterocyclic compounds and methods of use |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573967A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
JOP20190186A1 (en) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | Quinazoline compound |
US20200163970A1 (en) | 2017-02-03 | 2020-05-28 | Tohoku University | Heterocyclic compound |
WO2018172250A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
JOP20190272A1 (en) * | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
CN110869357A (en) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Compounds and methods of use thereof for treating cancer |
WO2018218070A2 (en) * | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
AU2018288841B2 (en) | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
CN107382742A (en) * | 2017-07-30 | 2017-11-24 | 梁江丽 | A kind of new synthetic method of fluorine 4 (trifluoromethyl) anilinechloride of 5 chlorine of fragrance intermediate containing trifluoromethyl 2 |
CN116003405A (en) * | 2017-09-08 | 2023-04-25 | 美国安进公司 | Inhibitors of KRAS G12C and methods of use thereof |
RS64182B1 (en) | 2017-11-15 | 2023-05-31 | Mirati Therapeutics Inc | Kras g12c inhibitors |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2019110751A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents |
CA3085259A1 (en) | 2017-12-13 | 2019-06-20 | Lupin Limited | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
US11453667B2 (en) * | 2018-01-19 | 2022-09-27 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor |
TW201942115A (en) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
BR112020020307A2 (en) * | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE |
US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
AU2019262589B2 (en) * | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
MA52496A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
TW202012415A (en) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | Chemical compounds |
WO2019217691A1 (en) * | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3100390A1 (en) * | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
JP2021176820A (en) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | Pharmaceutical composition comprising quinazoline compound as active ingredient |
JP2021176819A (en) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | Pharmaceutical composition comprising quinazoline compound as active ingredient |
EP3829580A1 (en) * | 2018-08-01 | 2021-06-09 | Araxes Pharma LLC | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
MX2021001706A (en) | 2018-08-16 | 2021-04-19 | Hoffmann La Roche | Fused ring compounds. |
AU2019346550A1 (en) | 2018-09-25 | 2021-04-22 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
EP3628664A1 (en) | 2018-09-25 | 2020-04-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Irreversible inhibitors of kras g12c mutant |
CN109232259B (en) * | 2018-09-27 | 2021-05-28 | 浙江理工大学 | Preparation method of nitroacetophenone |
TW202033518A (en) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c inhibitors |
US20210380595A1 (en) | 2018-10-24 | 2021-12-09 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis |
US20210395234A1 (en) * | 2018-10-26 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
WO2020089850A1 (en) * | 2018-11-01 | 2020-05-07 | Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional | Pharmaceutical compositions for the effective treatment of pancreatic cancer |
MX2018013438A (en) * | 2018-11-01 | 2022-07-20 | Centro De Investig Y De Estudios Avanzados Del I P N | Pharmaceutical compositions for the effective treatment of colorectal cancer. |
JP6941241B2 (en) * | 2018-11-09 | 2021-09-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Condensation ring compound |
JP2020090482A (en) * | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
EP3883565A1 (en) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
CA3120383A1 (en) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
JP2022517222A (en) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | KRAS G12C inhibitor |
EP3919483A4 (en) * | 2019-01-29 | 2022-02-09 | Brightgene Bio-medical Technology Co., Ltd. | Benzopyridone heterocyclic compound and use thereof |
CN113382774A (en) | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | Pharmaceutical combination comprising TNO155 and KRASG12C inhibitors |
WO2020173935A1 (en) | 2019-02-26 | 2020-09-03 | Boehringer Ingelheim International Gmbh | New isoindolinone substituted indoles and derivatives as ras inhibitors |
WO2020177629A1 (en) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | Spiro-substituted pyrimidine-fused cyclic compound, preparation method therefor and medical use thereof |
CN111662232B (en) * | 2019-03-06 | 2022-08-02 | 中国科学院上海药物研究所 | Small molecule compound with 2H-indazole structure and synthesis and application thereof |
KR20220012248A (en) * | 2019-04-22 | 2022-02-03 | 베타 파머수티컬 컴퍼니 리미티드 | Quinazoline compounds and their applications in pharmaceuticals |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
WO2020236940A1 (en) * | 2019-05-20 | 2020-11-26 | California Institute Of Technology | Kras g12c inhibitors and uses thereof |
MX2021014126A (en) | 2019-05-21 | 2022-01-04 | Amgen Inc | Solid state forms. |
WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
JP2022534765A (en) * | 2019-05-29 | 2022-08-03 | 上▲海▼翰森生物医▲薬▼科技有限公司 | Nitrogen-containing heterocyclic derivative regulator, method of preparation and use thereof |
CN112552294B (en) * | 2019-09-10 | 2023-12-19 | 上海翰森生物医药科技有限公司 | Piperazine heterocyclic derivative-containing inhibitor, preparation method and application thereof |
CN112047948B (en) * | 2019-06-06 | 2022-08-16 | 山东轩竹医药科技有限公司 | Kras mutant inhibitors |
DK3980417T3 (en) | 2019-06-10 | 2023-12-18 | Lupin Ltd | PRMT5-Inhibitorer |
WO2020259573A1 (en) * | 2019-06-25 | 2020-12-30 | 南京明德新药研发有限公司 | Seven-membered heterocyclic derivative acting as kras g12c mutant protein inhibitor |
CN112300173B (en) * | 2019-07-30 | 2021-10-01 | 上海凌达生物医药有限公司 | Nitrogen-containing polycyclic compounds, preparation method and application |
JP2022546043A (en) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | KRAS G12D inhibitor |
KR102176937B1 (en) * | 2019-09-11 | 2020-11-10 | 연세대학교 산학협력단 | A Composition for Preventing or Treating Metabolic Disorders Comprising Viperin Inhibitors as Active Ingredients |
KR102152974B1 (en) * | 2019-09-11 | 2020-09-07 | 연세대학교 산학협력단 | A Composition for Enhancing Thermogenesis In Vivo Comprising Viperin Inhibitors as Active Ingredients |
AU2020350745A1 (en) * | 2019-09-20 | 2022-04-07 | Jiangxi Jemincare Group Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
KR20220091480A (en) | 2019-09-24 | 2022-06-30 | 미라티 테라퓨틱스, 인크. | combination therapy |
WO2021063346A1 (en) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c inhibitor and application thereof |
US20230023066A1 (en) * | 2019-10-25 | 2023-01-26 | Merck Sharp & Dohme Corp. | N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
CN112225734B (en) * | 2019-10-25 | 2021-12-07 | 南京瑞捷医药科技有限公司 | KRAS G12C inhibitors and uses thereof |
MX2022005053A (en) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant. |
CN117645614A (en) * | 2019-10-30 | 2024-03-05 | 劲方医药科技(上海)有限公司 | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof |
US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
EP4051673A1 (en) | 2019-11-01 | 2022-09-07 | Syngenta Crop Protection AG | Pesticidally active fused bicyclic heteroaromatic compounds |
CN112778284B (en) * | 2019-11-01 | 2022-04-05 | 四川海思科制药有限公司 | Pyrimido-cyclic derivative and application thereof in medicine |
BR112022008565A2 (en) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHODS TO TREAT CANCER AND A RAS PROTEIN-RELATED DISORDER |
TW202132314A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
JP2023505100A (en) * | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
CN111377918B (en) * | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | KRAS inhibitor compound |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
US20230049402A1 (en) | 2019-11-29 | 2023-02-16 | Taiho Pharmaceutical Co., Ltd. | Novel phenol compound or salt thereof |
CN113024544A (en) * | 2019-12-09 | 2021-06-25 | 武汉誉祥医药科技有限公司 | Cyano-containing heterocyclic compound and application thereof |
ES2929700T3 (en) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | KRas g12c inhibitors |
CA3161278A1 (en) | 2019-12-20 | 2021-06-24 | Matthew Arnold Marx | Sos1 inhibitors |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
CN113061132B (en) * | 2020-01-01 | 2023-11-14 | 上海凌达生物医药有限公司 | Condensed ring lactam compound, preparation method and application |
CN113135924A (en) * | 2020-01-19 | 2021-07-20 | 广东东阳光药业有限公司 | Pyrimidine derivatives and their use in medicine |
GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
CN112159405B (en) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | Pyridopyrimidinone compounds and application thereof |
US20230150978A1 (en) | 2020-03-30 | 2023-05-18 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
JP2023523640A (en) * | 2020-04-29 | 2023-06-06 | シャンハイ リンジーン バイオファーマ カンパニー リミテッド | Benzothiazolyl biaryl compound, preparation method and use thereof |
WO2021245051A1 (en) * | 2020-06-02 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202210633A (en) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | A dbait molecule in combination with kras inhibitor for the treatment of cancer |
AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
EP4175947A1 (en) * | 2020-06-30 | 2023-05-10 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
CN113880827A (en) * | 2020-07-03 | 2022-01-04 | 苏州闻天医药科技有限公司 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
CN115052870B (en) * | 2020-08-02 | 2024-02-20 | 上海喆邺生物科技有限公司 | Aromatic compound and application thereof in antitumor drugs |
KR20230049679A (en) * | 2020-08-12 | 2023-04-13 | 제넨테크, 인크. | Synthesis of quinazoline compounds |
KR20230081726A (en) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
MX2023003060A (en) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer. |
EP4223761A1 (en) * | 2020-09-30 | 2023-08-09 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
TW202227441A (en) * | 2020-10-21 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | Quinazoline compound and pharmaceutical composition thereof |
BR112023007912A2 (en) * | 2020-10-30 | 2024-01-02 | Novartis Ag | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND |
JP2023547522A (en) * | 2020-11-06 | 2023-11-10 | タイリガンド バイオサイエンス(シャンハイ)リミテッド | KRas inhibitors for cancer treatment |
TW202227412A (en) * | 2020-11-24 | 2022-07-16 | 大陸商杭州多域生物技術有限公司 | Aromatic compound, and preparation method therefor and use thereof |
TW202235082A (en) | 2020-12-04 | 2022-09-16 | 美商美國禮來大藥廠 | Kras g12c inhibitors |
WO2022127847A1 (en) * | 2020-12-17 | 2022-06-23 | 广东东阳光药业有限公司 | Pyrimidone derivative and application thereof in drug |
WO2022127915A1 (en) * | 2020-12-18 | 2022-06-23 | 正大天晴药业集团股份有限公司 | Pyridopyrimidinone compound |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN115141215B (en) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | KRAS G12D protein inhibitors and uses thereof |
WO2022232318A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
AR125782A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
US20220396589A1 (en) | 2021-05-05 | 2022-12-15 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
CA3221180A1 (en) | 2021-06-24 | 2022-12-29 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
TW202315610A (en) * | 2021-07-23 | 2023-04-16 | 美商德洛斯股份有限公司 | Compositions and methods for inhibition of ras |
AU2022320304A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
AU2022336415A1 (en) | 2021-09-01 | 2024-01-04 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023039240A1 (en) * | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023045960A1 (en) * | 2021-09-22 | 2023-03-30 | 四川汇宇制药股份有限公司 | Pyridine derivative and use thereof |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
CN115974896A (en) * | 2021-10-15 | 2023-04-18 | 广东东阳光药业有限公司 | Novel pyrimidopyridine compounds, pharmaceutical compositions thereof and uses thereof |
TW202337432A (en) * | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
CN114507142A (en) * | 2022-01-28 | 2022-05-17 | 上海予君生物科技发展有限公司 | Preparation process of 2-chloro-4-fluoro-5-nitrobenzaldehyde |
WO2023152255A1 (en) | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023165581A1 (en) * | 2022-03-03 | 2023-09-07 | 四川汇宇制药股份有限公司 | Pyridine derivative and use thereof |
WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
WO2023196959A1 (en) | 2022-04-07 | 2023-10-12 | Eli Lilly And Company | Process for making a kras g12c inhibitor |
WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2023247360A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
WO2024022471A1 (en) * | 2022-07-28 | 2024-02-01 | 上海湃隆生物科技有限公司 | Kras inhibitor compound |
GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
US510A (en) | 1837-12-07 | soeel | ||
US5863A (en) | 1848-10-17 | Matthias p | ||
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
PT821671E (en) | 1995-04-20 | 2001-04-30 | Pfizer | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS |
DE69624081T2 (en) | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix metalloprotease inhibitors |
JP3195756B2 (en) | 1996-07-04 | 2001-08-06 | 公子 吉水 | Lubrication auxiliary |
WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
ES2202796T3 (en) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | DERIVATIVES OF ARILSULFONYLAMINOHYDROXAMIC ACIDS. |
EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
JP3710489B2 (en) | 1997-02-11 | 2005-10-26 | ファイザー・インク | Arylsulfonylhydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
US6890747B2 (en) * | 2000-10-23 | 2005-05-10 | Warner-Lambert Company | Phosphoinositide 3-kinases |
DE60227794D1 (en) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | NITROGENIC COMPOUND WITH CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF |
US9259426B2 (en) * | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
WO2011082285A1 (en) * | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
WO2011113512A1 (en) * | 2010-03-16 | 2011-09-22 | Merck Patent Gmbh | Morpholinylquinazolines |
JP2013107855A (en) * | 2011-11-22 | 2013-06-06 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
-
2014
- 2014-10-10 KR KR1020167011577A patent/KR20160076519A/en not_active Application Discontinuation
- 2014-10-10 EA EA201690752A patent/EA033689B9/en active IP Right Revival
- 2014-10-10 BR BR112016008016A patent/BR112016008016B8/en active IP Right Grant
- 2014-10-10 CA CA2926328A patent/CA2926328C/en active Active
- 2014-10-10 WO PCT/US2014/060036 patent/WO2015054572A1/en active Application Filing
- 2014-10-10 JP JP2016521333A patent/JP6559123B2/en active Active
- 2014-10-10 UA UAA201605067A patent/UA119971C2/en unknown
- 2014-10-10 EP EP14799915.5A patent/EP3055290B1/en active Active
- 2014-10-10 SG SG11201602662YA patent/SG11201602662YA/en unknown
- 2014-10-10 MX MX2016004360A patent/MX2016004360A/en unknown
- 2014-10-10 CN CN201480055783.1A patent/CN106488910B/en active Active
- 2014-10-10 EP EP19195037.7A patent/EP3636639A1/en active Pending
- 2014-10-10 AU AU2014331794A patent/AU2014331794C1/en active Active
-
2016
- 2016-03-21 PH PH12016500538A patent/PH12016500538A1/en unknown
- 2016-03-21 IL IL244699A patent/IL244699B/en active IP Right Grant
- 2016-04-05 ZA ZA2016/02245A patent/ZA201602245B/en unknown
- 2016-04-08 NI NI201600049A patent/NI201600049A/en unknown
- 2016-04-19 NO NO20160646A patent/NO20160646A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN106488910B (en) | 2020-07-31 |
PH12016500538B1 (en) | 2016-06-13 |
UA119971C2 (en) | 2019-09-10 |
WO2015054572A1 (en) | 2015-04-16 |
AU2014331794C1 (en) | 2019-09-12 |
JP6559123B2 (en) | 2019-08-14 |
NO20160646A1 (en) | 2016-04-19 |
EA201690752A1 (en) | 2016-07-29 |
CA2926328C (en) | 2022-11-29 |
EA033689B1 (en) | 2019-11-18 |
BR112016008016B1 (en) | 2021-01-19 |
IL244699A0 (en) | 2016-04-21 |
JP2016532656A (en) | 2016-10-20 |
BR112016008016B8 (en) | 2023-09-26 |
NI201600049A (en) | 2016-05-20 |
MX2016004360A (en) | 2016-08-19 |
AU2014331794B2 (en) | 2019-04-04 |
NZ719076A (en) | 2021-11-26 |
KR20160076519A (en) | 2016-06-30 |
CN106488910A (en) | 2017-03-08 |
PH12016500538A1 (en) | 2016-06-13 |
BR112016008016A2 (en) | 2017-09-12 |
EP3636639A1 (en) | 2020-04-15 |
EP3055290B1 (en) | 2019-10-02 |
CA2926328A1 (en) | 2015-04-16 |
AU2014331794A1 (en) | 2016-04-21 |
IL244699B (en) | 2020-11-30 |
EA033689B9 (en) | 2020-04-29 |
EP3055290A1 (en) | 2016-08-17 |
ZA201602245B (en) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201602245B (en) | Inhibitors of kras g12c | |
HK1215029A1 (en) | Covalent inhibitors of kras g12c kras g12c | |
IL256946B (en) | Bromodomain inhibitors | |
IL279682A (en) | Benzoquinolone inhibitors of vmat2 | |
HK1224297A1 (en) | Bromodomain inhibitors | |
HK1212691A1 (en) | Inhibitors of the kynurenine pathway | |
IL241123A0 (en) | Dihydro-pyrrolopyridinone bromodomain inhibitors | |
HK1220459A1 (en) | Kinase inhibitors | |
HK1219421A1 (en) | Combination of kinase inhibitors and uses thereof | |
HK1219104A1 (en) | Kinase inhibitors | |
HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
EP3632467C0 (en) | Inhibitors of complement factor h | |
HK1221645A1 (en) | Benzoquinolone inhibitors of vmat2 vmat2 | |
IL240763B (en) | Halogenopyrazoles as inhibitors of therombin | |
GB201323021D0 (en) | Use of kinase inhibitors | |
GB201321227D0 (en) | Use of kinase inhibitors | |
GB201307155D0 (en) | Kinase inhibitors |